STAT

Opinion: Lobotomies were once used to treat this gut disease, part of a shameful medical history

I am searching for "patient zero," the first person to be given a barbaric lobotomy to "cure" her ulcerative colitis. Can you help me find her?
Source: Wellcome Images

In May 1951, a 35-year-old Boston woman who had been treated for years for ulcerative colitis and a variety of mental disorders — with little success — entered the Lahey Clinic in Burlington, Mass., to have a lobotomy. Her doctors drilled two holes into her skull and cut or melted away two wedges of her brain’s cerebral cortex using a technique developed by James Poppen, a Lahey neurosurgeon.

By August, according to Walter I. Tucker, a Lahey psychiatrist, she was largely free of her physical and mental ailments. By December, after a period of confusion and “laziness,” she was socially active and going to dances, Tucker wrote in the Lahey Clinic Bulletin. She was also gaining weight and working regularly, and was free of “inappropriate worries, phobias, obsessions, and compulsions.” There was no sign of colitis. Her mother, with whom she lived, “was amazed at the change and thinks that the patient is better than she has ever been in her life,” Tucker wrote.

Like most patients in medical history, we don’t know her name. And we have no idea whether she went on to live

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About A J&J Cough Syrup, A Pfizer And Moderna Patent Suit, And More
A Johnson & Johnson children’s cough syrup found to contain unsafe levels of a toxic industrial solvent was sold in six African countries.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About BIO’s China Challenge, Zepbound Shortages, And More
BIO's about-face in its relationship with WuXi AppTec illustrates the difficulty the biotech industry faces in dealing with an issue that is moving fast and forcefully.
STAT1 min read
Opinion: STAT+: How AI Can Help Satisfy FDA’s Drug, Device Diversity Requirements
To meet the Food and Drug Omnibus Reform Act, companies must rethink their current clinical trial strategies. Including AI and machine learning approaches can help.

Related Books & Audiobooks